First Ozempic Generics Launch in Canada, Pressuring Novo Nordisk Revenue

Key Facts

Canada has introduced the first generic versions of the blockbuster drug Ozempic, serving as a critical test case for Novo Nordisk as it faces patent expirations. The availability of generic semaglutide is expected to trigger a decline in international revenue for the pharmaceutical giant's flagship product. Analysts suggest that this introduction will foster intense price competition, which typically results in a reduced market share for the original manufacturer. The Canadian market is being viewed as a precedent for how other global regions will react as legal protections for the drug begin to lapse. Investors are closely monitoring Novo Nordisk's ability to maintain profit margins amidst these emerging competitive pressures. This shift represents a significant strategic challenge for the company, which has relied heavily on the rapid growth of its diabetes and obesity franchise.